National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Selparcatinib (Retsevmo®) for NSCLC. HTA ID: 21021

Selparcatinib as monotherapy is indicated for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 08/06/2021
Rapid review completed 29/06/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.